Log in
ASX:MSB

Mesoblast Limited (MSB.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$3.39
MA: A$3.39
A$3.39
52-Week Range N/A
Volume10.19 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-3-96396036
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.41 million
Book ValueA$0.92 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Receive MSB News and Ratings via Email

Sign-up to receive the latest news and ratings for MSB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mesoblast Limited (MSB.AX) (ASX:MSB) Frequently Asked Questions

What stocks does MarketBeat like better than Mesoblast Limited (MSB.AX)?

Wall Street analysts have given Mesoblast Limited (MSB.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mesoblast Limited (MSB.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Mesoblast Limited (MSB.AX)'s next earnings date?

Mesoblast Limited (MSB.AX) is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Mesoblast Limited (MSB.AX)
.

How were Mesoblast Limited (MSB.AX)'s earnings last quarter?

Mesoblast Limited (MSB.AX) (ASX:MSB) posted its quarterly earnings results on Thursday, February, 21st. The company reported ($0.09) earnings per share for the quarter.
View Mesoblast Limited (MSB.AX)'s earnings history
.

Who are some of Mesoblast Limited (MSB.AX)'s key competitors?

What other stocks do shareholders of Mesoblast Limited (MSB.AX) own?

Who are Mesoblast Limited (MSB.AX)'s key executives?

Mesoblast Limited (MSB.AX)'s management team includes the following people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 63, Pay $1.67M)
  • Mr. Josh Muntner BFA, M.B.A., Chief Financial Officer (Age 51, Pay $934.84k)
  • Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons), Gen. Counsel & Corp. Exec. (Age 52)
  • Mr. Michael Schuster M.B.A., MS, BSc, MBA, Head of Pharma Partnering (Age 43)
  • Dr. Eric Strati M.B.A., Ph.D., Pharm.D., MBA, Sr. VP of Commercial
  • Dr. Fred Grossman, Chief Medical Officer
  • Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S., Chief Operating Officer (Age 56)
  • Sir Jonathan Richard Symonds B.A., F.C.A., CBE, BA, FCA, Head of Corp. Fin. & Strategy (Age 61)
  • Ms. Julie Meldrum, Global Head of Corp. Communications
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders

What is Mesoblast Limited (MSB.AX)'s stock symbol?

Mesoblast Limited (MSB.AX) trades on the ASX under the ticker symbol "MSB."

How big of a company is Mesoblast Limited (MSB.AX)?

Mesoblast Limited (MSB.AX) has a market capitalization of $0.00 and generates $16.41 million in revenue each year. Mesoblast Limited (MSB.AX) employs 102 workers across the globe.

What is Mesoblast Limited (MSB.AX)'s official website?

The official website for Mesoblast Limited (MSB.AX) is www.mesoblast.com.

How can I contact Mesoblast Limited (MSB.AX)?

Mesoblast Limited (MSB.AX)'s mailing address is L 38 55 Collins St, MELBOURNE, VIC 3000, Australia. The company can be reached via phone at +61-3-96396036.

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.